EP1183540A1 - Methodes permettant de prevoir et/ou diagnostiquer les risques de cancers gastriques - Google Patents

Methodes permettant de prevoir et/ou diagnostiquer les risques de cancers gastriques

Info

Publication number
EP1183540A1
EP1183540A1 EP00924979A EP00924979A EP1183540A1 EP 1183540 A1 EP1183540 A1 EP 1183540A1 EP 00924979 A EP00924979 A EP 00924979A EP 00924979 A EP00924979 A EP 00924979A EP 1183540 A1 EP1183540 A1 EP 1183540A1
Authority
EP
European Patent Office
Prior art keywords
subject
γlfn
level
pylori
gastric cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00924979A
Other languages
German (de)
English (en)
Other versions
EP1183540A4 (fr
Inventor
Robert Llewellyn Clancy
Gerald Pang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onco Alert Pty Ltd
Original Assignee
Onco Alert Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onco Alert Pty Ltd filed Critical Onco Alert Pty Ltd
Publication of EP1183540A1 publication Critical patent/EP1183540A1/fr
Publication of EP1183540A4 publication Critical patent/EP1183540A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/205—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Campylobacter (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5406—IL-4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Definitions

  • the present invention relates to methods of predicting the risk of developing
  • Thl characterised by production of ⁇ interferon ( ⁇ lFN) but not interleukin-4
  • H. pylori is an essential component of the chain of events leading to chronic
  • the present invention provides a method of diagnosing
  • infection including:
  • H. pylori antibody in the subject compared to the control indicates the presence and/or
  • the present invention provides a method of
  • Helicohacter infection including:
  • the present invention provides a method of diagnosing
  • infection including:
  • the present invention provides a method of
  • Helicohacter infection including a combination of a method according to the first aspect
  • the present invention provides a method of diagnosing
  • the Helicohacter infection is a Helicohacter pylori infection.
  • the IgG2 anti-H. pylori antibody, ⁇ lFN and/or IL-4 levels are selected from the group consisting of: IL-4, IL-4, and/or IL-4 levels.
  • the IgG2 anti-H. pylori antibody and/or ⁇ lFN and/or IL-4 are detected
  • the assay may, however, also be a laboratory-based test.
  • the assay is an antibody assay although it will be understood that other
  • the present invention provides a method of predicting the present invention's performance of a cell.
  • the blood may be purified to provide an
  • enriched white blood cell population and the white blood cell population may be further
  • the present invention provides a method of
  • IL-4-producing cells in the subject's gastric mucosa with a predetermined control level wherein a reduction in the level of IgG2 anti-H.pylori antibody- and/or ⁇ lFN-producing
  • the cells are derived from a biopsy sample.
  • Control levels of IgG2 anti-H. pylori antibody, IL-4 and/or ⁇ lFN can be established
  • H pylori infection or they can be established in samples from subjects with
  • control levels are not or the like. In certain cases, in which subjects are followed prospectively, control levels
  • control levels may be internal levels, i.e. the subject's own control levels.
  • the method of the present invention can also be used to diagnose and/or determine
  • ⁇ lFN or IL-4 to other parameters such as, for example total IgG anti-H. pylori antibody
  • ratios may require that specific ratios be utilised, such as the ratio of IL-4: ⁇ IFN, IgG2:total IgG
  • Thl pattern of cytokine eg, ⁇ lNF
  • IL-4 was not
  • gastric mucosa can be used as an indicator of H. pylori status.
  • IgG anti-H. pylori can be utilised as a general
  • the invention also relates to the measurement of the IgG2
  • Example 1 Determination of cytokine and antibody levels in a blood sample
  • the standard assay involves coating microwells of a 96- well microtitre plate with
  • IL-4 captured by IL-4 MoAb in each well is measured by ELISA ( Figures 1 and 2).
  • IL-4 bound is detected by reaction with biotinylated anti-IL-4 antibody and
  • Gastric T cells are isolated from biopsy tissues obtained at endoscopy. The tissues
  • Table 2 provides an example of the predictions/diagnoses which can be made on
  • Example 3 Frequency of IL-4 and ⁇ lFN producing cells in peripheral blood
  • Intracellular cytokine staining and detection by flow cytometry is used to estimate
  • ⁇ IFN:IL-4 producing cells were higher in subjects infected with H. pylori than in
  • Controls contained no responder cells or responder cells in medium and rlL-
  • IL-4 is unstable an antibody capture method is used with bound IL-4 measured by ELISA using a matched antibody pair (Endogen/CSL). ⁇ lFN
  • peripheral blood mononuclear cells producing IL-4 and ⁇ lFN are calculated by
  • Figures 1 to 5 provide results obtained utilising the tests exemplified below in studies of

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur des méthodes permettant de prévoir les risques de développement de cancers, et en particulier sur une méthode permettant de prévoir et/ou diagnostiquer les risques de cancers gastriques chez des sujets infectés par l'Helicobacter.
EP00924979A 1999-05-14 2000-05-15 Methodes permettant de prevoir et/ou diagnostiquer les risques de cancers gastriques Withdrawn EP1183540A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPQ0377A AUPQ037799A0 (en) 1999-05-14 1999-05-14 Methods for diagnosing and/or predicting the risk of gastric cancer
AUPQ037799 1999-05-14
PCT/AU2000/000441 WO2000070348A1 (fr) 1999-05-14 2000-05-15 Methodes permettant de prevoir et/ou diagnostiquer les risques de cancers gastriques

Publications (2)

Publication Number Publication Date
EP1183540A1 true EP1183540A1 (fr) 2002-03-06
EP1183540A4 EP1183540A4 (fr) 2007-07-04

Family

ID=3814581

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00924979A Withdrawn EP1183540A4 (fr) 1999-05-14 2000-05-15 Methodes permettant de prevoir et/ou diagnostiquer les risques de cancers gastriques

Country Status (10)

Country Link
EP (1) EP1183540A4 (fr)
JP (1) JP2002544520A (fr)
KR (1) KR20020033093A (fr)
CN (1) CN1355885A (fr)
AU (1) AUPQ037799A0 (fr)
BR (1) BR0010558A (fr)
CA (1) CA2372761A1 (fr)
HK (1) HK1044988A1 (fr)
MX (1) MXPA01011721A (fr)
WO (1) WO2000070348A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ854100A0 (en) * 2000-07-03 2000-07-27 Helirad Pty Ltd Methods for monitoring treatment of helicobacter infection
GB2430031A (en) * 2005-09-07 2007-03-14 Ethicon Inc Diagnostic markers of wound infection
JP2014530350A (ja) * 2011-09-14 2014-11-17 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 腎臓毒性を評価するための手段及び方法
JP6707248B2 (ja) * 2013-12-05 2020-06-10 学校法人北里研究所 胃癌細胞の検出方法、及び胃癌細胞検出キット
RU2706118C1 (ru) * 2019-04-30 2019-11-14 Федеральное государственное бюджетное образовательное учреждение высшего образования "Национальный исследовательский Мордовский государственный университет им. Н.П. Огарёва" Способ прогнозирования предраковых заболеваний желудка
CN117143234B (zh) * 2023-08-29 2024-05-03 武汉爱博泰克生物科技有限公司 抗大鼠白细胞介素-4蛋白的单克隆抗体及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012965A1 (fr) * 1994-10-20 1996-05-02 Genelabs Diagnostics Pte Ltd. Methodes de diagnostic de l'helicobacter pylori et necessaires correspondants
IT1289578B1 (it) * 1996-12-06 1998-10-15 Sanitaria Scaligera Spa Immunopurificazione di un antigene dall'apparente peso molecolare di 16 +- 2 kda dell' helicobacter pylori e metodi per la sua

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BLASER MARTIN J ET AL: "Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach" CANCER RESEARCH, vol. 55, no. 10, 1995, pages 2111-2115, XP002416860 ISSN: 0008-5472 *
BONTKES H J ET AL: "IGG SUBCLASS RESPONSE TO HELICOBACTER PYLORI IN PATIENTS WITH CHRONIC ACTIVE GASTRITIS AND DUODENAL ULCER" SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol. 27, no. 2, 1992, pages 129-133, XP009077511 ISSN: 0036-5521 *
FOX JAMES G ET AL: "Mice carrying a truncated Apc gene have diminished gastric epithelial proliferation, gastric inflammation, and humoral immunity in response to Helicobacter felis infection" CANCER RESEARCH, vol. 57, no. 18, 1997, pages 3972-3978, XP002416862 ISSN: 0008-5472 *
RUDI JOCHEN ET AL: "Serum antibodies against Helicobacter pylori proteins VacA and CagA are associated with increased risk for gastric adenocarcinoma" DIGESTIVE DISEASES AND SCIENCES, vol. 42, no. 8, 1997, pages 1652-1659, XP002416861 ISSN: 0163-2116 *
See also references of WO0070348A1 *

Also Published As

Publication number Publication date
WO2000070348A1 (fr) 2000-11-23
JP2002544520A (ja) 2002-12-24
CN1355885A (zh) 2002-06-26
CA2372761A1 (fr) 2000-11-23
KR20020033093A (ko) 2002-05-04
MXPA01011721A (es) 2003-09-10
EP1183540A4 (fr) 2007-07-04
AUPQ037799A0 (en) 1999-06-10
HK1044988A1 (zh) 2002-11-08
BR0010558A (pt) 2002-02-19

Similar Documents

Publication Publication Date Title
JP2020180975A (ja) 複数の抗体を含むキット
EP3180621B1 (fr) Analyse computationnelle de données biologiques au moyen d'un collecteur et d'un hyperplan
CN101523217B (zh) 基于ip-10的免疫学监测
Vaira et al. invasive and non‐invasive tests for Helicobacter pylori infection
EP4184167A1 (fr) Diagnostic précoce d'infections
Chen et al. Prospective evaluation of 64 serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting
Matsumoto et al. Anti‐programmed cell death‐1 antibody as a new serological marker for type 1 autoimmune hepatitis
WO2018029690A1 (fr) Système et procédé d'analyse de données biologiques
WO2013146993A1 (fr) Procédé de détection du degré de malignité d'une unité de cellule tumorale circulante et trousse pour celui-ci
CA2200363A1 (fr) Methode et trousse de detection d'anticorps diriges contre un virus
WO2008125262A1 (fr) Régulation auto-immune du cancer de la prostate par l'annexine a3
CN111735961A (zh) 急性呼吸窘迫综合征检测试剂盒
Ouellette et al. Evolving point-of-care diagnostics using up-converting phosphor bioanalytical systems
WO2000070348A1 (fr) Methodes permettant de prevoir et/ou diagnostiquer les risques de cancers gastriques
US20080038760A1 (en) Method for Detecting Anti-Transglutaminase Antibodies
US20060216763A1 (en) Methods for predicting and/or diagnosing the risk of gastric cancer
CN1987468B (zh) 血管内皮生长因子时间分辨荧光免疫分析方法及试剂盒
RU2426130C2 (ru) Экспресс-тест для диагностирования болезни альцгеймера
CN115902240A (zh) 一种抗磷脂抗体谱检测试剂盒及其应用
JP2020020649A (ja) 胃癌細胞におけるｋｋ−ｌｃ−１の発現を予測する方法及びキット
AU4386200A (en) Methods for predicting and/or diagnosing the risk of gastric cancer
AU2004242535A1 (en) Methods for predicting and/or diagnosing the risk of gastric cancer
WO2013003898A1 (fr) Procédé pour de détection d'un cancer chez un patient
US20070122855A1 (en) Methods for diagnosing hepatocellular carcinoma
CA2486119A1 (fr) Methodes d'essai de compatibilite croisee specifique du donneur

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011214

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/50 20060101ALI20070228BHEP

Ipc: G01N 33/68 20060101AFI20070228BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070605

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070904